Drs Hanna and Kandula discuss the significance of the FDA approval of toripalimab in nasopharyngeal carcinoma; pivotal data from the JUPITER-02 and POLARIS-02 trials; and how this regulatory decision increases the importance of multidisciplinary collaboration.
Giving the immunotherapy nivolumab to patients with oral proliferative leukoplakia not only reduces lesions but also may prevent cancer progression, suggests the first study in the preventive setting.
- Stage one efficacy threshold achieved in dose expansion in patients with squamous cell carcinoma of the head and neck- Webinar to review data to be held Monday, September 12th at 10:30 a.m. ET, featuring Principal Investigator Glenn J. Hanna, M.D.CAMBRIDGE, Mass. (BUSINESS WIRE) Bicara Therapeutics, a clinical-s.
Stage one efficacy threshold achieved in dose expansion in patients with squamous cell carcinoma of the head and neck Webinar to review data to be held Monday, September 12th at 10:30 a.m. ET, featuring